|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4741900A
(en)
|
1982-11-16 |
1988-05-03 |
Cytogen Corporation |
Antibody-metal ion complexes
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8430252D0
(en)
|
1984-11-30 |
1985-01-09 |
Beecham Group Plc |
Compounds
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
ES2054667T3
(es)
|
1986-04-28 |
1994-08-16 |
Cetus Oncology Corp |
Anticuerpos monoclonales contra c5a y des-arg74-c5a, su produccion y uso.
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5256642A
(en)
|
1988-04-01 |
1993-10-26 |
The Johns Hopkins University |
Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
|
|
NZ230747A
(en)
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5166322A
(en)
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
|
US5244800A
(en)
|
1990-04-27 |
1993-09-14 |
The Uab Research Foundation |
Crystals of human complement factor d that are triclinic
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
AU675916B2
(en)
|
1991-06-14 |
1997-02-27 |
Genentech Inc. |
Method for making humanized antibodies
|
|
AU2147192A
(en)
|
1991-06-28 |
1993-01-25 |
Genentech Inc. |
Method of stimulating immune response using growth hormone
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
WO1993016185A2
(en)
|
1992-02-06 |
1993-08-19 |
Creative Biomolecules, Inc. |
Biosynthetic binding protein for cancer marker
|
|
US5456909A
(en)
|
1992-08-07 |
1995-10-10 |
T Cell Sciences, Inc. |
Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
|
|
DK0656789T3
(da)
|
1992-08-21 |
1998-08-24 |
Genentech Inc |
Fremgangsmåde til behandling af en LFA-1-medieretforstyrrelse.
|
|
JPH08506095A
(ja)
|
1992-11-25 |
1996-07-02 |
アムジェン ボールダー インコーポレイテッド |
改変インシュリン様成長因子
|
|
US5861156A
(en)
|
1993-01-08 |
1999-01-19 |
Creative Biomolecules |
Methods of delivering agents to target cells
|
|
JPH08508296A
(ja)
|
1993-04-07 |
1996-09-03 |
アムジエン・ブルダー・インコーポレーテッド |
インシュリン様成長因子結合タンパク質の使用方法
|
|
US5856300A
(en)
|
1994-05-12 |
1999-01-05 |
T Cell Sciences, Inc. |
Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
|
|
US5679546A
(en)
|
1993-09-24 |
1997-10-21 |
Cytomed, Inc. |
Chimeric proteins which block complement activation
|
|
US5627264A
(en)
|
1994-03-03 |
1997-05-06 |
Alexion Pharmaceuticals, Inc. |
Chimeric complement inhibitor proteins
|
|
AU2191795A
(en)
|
1994-03-23 |
1995-10-09 |
Alexion Pharmaceuticals, Inc. |
Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
|
|
US5534615A
(en)
|
1994-04-25 |
1996-07-09 |
Genentech, Inc. |
Cardiac hypertrophy factor and uses therefor
|
|
US5919623A
(en)
|
1994-04-27 |
1999-07-06 |
St. James's And Seacroft University Hospitals Nhs Trust |
Nucleic acid mutation assays
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5679345A
(en)
|
1994-06-02 |
1997-10-21 |
The Johns Hopkins University |
Method for preventing complement-dependent rejection of organ or tissue transplants
|
|
US5681736A
(en)
|
1994-10-05 |
1997-10-28 |
Antex Biologics, Inc. |
Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
CA2658039A1
(en)
|
1995-09-21 |
1997-03-27 |
Genentech, Inc. |
Human growth hormone variants
|
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
|
US20050197285A1
(en)
|
1997-03-07 |
2005-09-08 |
Rosen Craig A. |
Human secreted proteins
|
|
WO1999040100A1
(en)
|
1998-02-09 |
1999-08-12 |
Human Genome Sciences, Inc. |
45 human secreted proteins
|
|
US6472520B2
(en)
|
1997-03-21 |
2002-10-29 |
The Trustees Of Columbia University In The City Of New York |
Rat PEG-3 promoter
|
|
ES2236634T3
(es)
|
1997-04-07 |
2005-07-16 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US5994511A
(en)
*
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
|
EP1881005B1
(en)
|
1997-07-14 |
2013-04-03 |
Bolder Biotechnology, Inc. |
Derivatives of G-CSF and related proteins
|
|
JP2001513576A
(ja)
|
1997-08-26 |
2001-09-04 |
グリアテック インコーポレイテッド |
側副経路を介する補体活性化を阻害するためのプロセス
|
|
US6410708B1
(en)
|
1997-11-21 |
2002-06-25 |
Genentech, Inc. |
Nucleic acids encoding A-33 related antigen polypeptides
|
|
DK1481989T3
(da)
|
1997-11-21 |
2008-08-25 |
Genentech Inc |
A-33-beslægtede antigener og deres farmakologiske anvendelser
|
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
|
US7282565B2
(en)
|
1998-03-20 |
2007-10-16 |
Genentech, Inc. |
PRO362 polypeptides
|
|
US8007798B2
(en)
|
1997-11-21 |
2011-08-30 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
US7419663B2
(en)
|
1998-03-20 |
2008-09-02 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
US7005504B2
(en)
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
|
BRPI9909220B1
(pt)
|
1998-02-20 |
2018-09-18 |
Genentech Inc |
hibridoma, anticorpo monoclonal, anticorpo humanizado, anticorpo quimérico, anticorpo desimunizado ou fragmento de tais anticorpos
|
|
US6956107B2
(en)
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
|
ES2312205T3
(es)
|
1998-03-10 |
2009-02-16 |
Genentech, Inc. |
Nuevo polipeptido y acidos nucleicos que lo codifican.
|
|
AU5587799A
(en)
|
1998-08-27 |
2000-03-21 |
Incyte Pharmaceuticals, Inc. |
Protein transport-associated molecules
|
|
US6376653B1
(en)
|
1998-09-28 |
2002-04-23 |
Smithkline Beecham Plc |
Tie2 antagonist antibodies
|
|
KR100468977B1
(ko)
|
1998-12-16 |
2005-02-02 |
제넨테크, 인크. |
분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
|
|
DK1484338T3
(da)
|
1998-12-22 |
2007-06-11 |
Genentech Inc |
Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst
|
|
NZ539776A
(en)
|
1999-01-15 |
2006-12-22 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
AU3514400A
(en)
|
1999-03-08 |
2000-09-28 |
Genentech Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
PL207994B1
(pl)
|
1999-03-11 |
2011-02-28 |
Serono Lab |
Polipeptyd, skierowane przeciw niemu przeciwciało i ich zastosowanie w medycynie oraz kodujące go poli- lub oligonukleotydy
|
|
US6642353B1
(en)
|
1999-03-17 |
2003-11-04 |
Chugai Seiyaku Kabushiki Kaisha |
Peptide ligands for the erythropoietin receptor
|
|
AU2883900A
(en)
|
1999-07-07 |
2001-01-30 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
EP1234030A4
(en)
|
1999-11-19 |
2003-05-07 |
Human Genome Sciences Inc |
18 HUMAN SECRETED PROTEINS
|
|
CA2496312A1
(en)
|
1999-12-01 |
2001-06-07 |
Kevin P. Baker |
Colon tumour marker pro4799 polypeptides and nucleic acids encoding the same
|
|
WO2001058526A2
(en)
|
2000-02-10 |
2001-08-16 |
Alexion Pharmaceuticals, Inc. |
Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
|
|
US6821775B1
(en)
|
2000-02-11 |
2004-11-23 |
Genvec, Inc. |
Viral vector encoding pigment epithelium-derived factor
|
|
ES2329010T3
(es)
|
2000-03-23 |
2009-11-20 |
Genentech, Inc. |
Inhibidores anti-c2/c2a de la activacion del complemento.
|
|
EP2026073B1
(en)
|
2000-04-29 |
2016-03-30 |
University Of Iowa Research Foundation |
Diagnostics and therapeutics for macular degeneration-related disorders
|
|
CA2412211A1
(en)
|
2000-06-23 |
2002-01-03 |
Genetech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
EP1309685A2
(en)
|
2000-07-20 |
2003-05-14 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
EP3031827A1
(en)
|
2000-10-10 |
2016-06-15 |
Genentech, Inc. |
Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
|
|
WO2002030463A2
(en)
|
2000-10-12 |
2002-04-18 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
AU2002211747B2
(en)
|
2000-10-13 |
2007-11-29 |
Biogen Idec Ma Inc. |
Humanized anti-LT-Beta-R antibodies
|
|
IL156618A0
(en)
|
2000-12-28 |
2004-01-04 |
Altus Biologics Inc |
Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
|
|
US20040077575A1
(en)
|
2002-01-11 |
2004-04-22 |
Giordano Giovan Giacomo |
Inhibition of pathological angiogenesis in vivo
|
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
|
CN100391537C
(zh)
|
2001-08-17 |
2008-06-04 |
建南德克公司 |
结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
|
|
CA2461292A1
(en)
|
2001-10-02 |
2003-04-10 |
Genentech, Inc. |
Apo-2 ligand variants and uses thereof
|
|
CA2489348A1
(en)
|
2002-06-24 |
2003-12-31 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
|
AU2003294210A1
(en)
|
2002-07-31 |
2004-05-04 |
Seattle Genetics, Inc |
Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
|
TWI323265B
(en)
|
2002-08-06 |
2010-04-11 |
Glaxo Group Ltd |
Antibodies
|
|
AU2003258714A1
(en)
|
2002-09-06 |
2004-03-29 |
Cytos Biotechnology Ag |
Immune modulatory compounds and methods
|
|
US7816497B2
(en)
|
2002-10-30 |
2010-10-19 |
University Of Kentucky |
Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
|
|
US7595430B2
(en)
|
2002-10-30 |
2009-09-29 |
University Of Kentucky Research Foundation |
Methods and animal model for analyzing age-related macular degeneration
|
|
JP2006518749A
(ja)
|
2003-02-21 |
2006-08-17 |
タノックス インコーポレーテッド |
虚血再灌流障害に伴う組織損傷を予防及び治療するための方法
|
|
RU2232991C1
(ru)
|
2003-04-09 |
2004-07-20 |
Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" |
Способ определения функциональной активности фактора d комплемента человека
|
|
KR100512483B1
(ko)
|
2003-05-07 |
2005-09-05 |
선바이오(주) |
신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
|
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
|
EP2267028A3
(en)
|
2003-06-30 |
2011-07-27 |
Domantis Limited |
Dual specific single domain antibodies (dAb) conjugated to PEG
|
|
WO2005014849A2
(en)
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
WO2005025509A2
(en)
|
2003-09-11 |
2005-03-24 |
Board Of Regents, The University Of Texas System |
Methods and materials for treating autoimmune diseases and conditions
|
|
US20050169921A1
(en)
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
|
US7127355B2
(en)
|
2004-03-05 |
2006-10-24 |
Perlegen Sciences, Inc. |
Methods for genetic analysis
|
|
US20090087854A1
(en)
|
2007-09-27 |
2009-04-02 |
Perlegen Sciences, Inc. |
Methods for genetic analysis
|
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
|
BRPI0516284A
(pt)
|
2004-09-23 |
2008-09-02 |
Genentech Inc |
anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
|
|
BRPI0518289A2
(pt)
|
2004-11-18 |
2008-11-11 |
Univ Yale |
mÉtodos e composiÇÕes para o tratamento de desordens oculares
|
|
WO2006071856A2
(en)
|
2004-12-23 |
2006-07-06 |
Glycofi, Inc. |
Immunoglobulins comprising predominantly a man5glcnac2 glycoform
|
|
EP2319940A1
(en)
|
2005-01-04 |
2011-05-11 |
Hitachi Chemical Company, Ltd. |
Primer generation rolling circle amplification
|
|
KR20070112801A
(ko)
|
2005-02-14 |
2007-11-27 |
유니버시티 오브 아이오와 리써치 파운데이션 |
연령관련 황반 변성의 치료 및 진단용 방법 및 시약
|
|
WO2006133295A2
(en)
|
2005-06-08 |
2006-12-14 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
SUSCEPTIBILITY GENES FOR AGE-RELATED MACULOPATHY (ARM) ON CHROMOSOME 10q26
|
|
WO2007044668A2
(en)
|
2005-10-08 |
2007-04-19 |
Potentia Pharmaceuticals, Inc. |
Compstatin and analogs thereof for eye disorders
|
|
NZ567483A
(en)
|
2005-11-04 |
2012-04-27 |
Genentech Inc |
Use of complement pathway inhibitors to treat ocular diseases
|
|
US20070190057A1
(en)
|
2006-01-23 |
2007-08-16 |
Jian Wu |
Methods for modulating mannose content of recombinant proteins
|
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
|
US20080146501A1
(en)
|
2006-02-13 |
2008-06-19 |
University Of Iowa Research Foundation |
Protective complement proteins and age-related macular degeneration
|
|
EP2004643A1
(en)
|
2006-03-31 |
2008-12-24 |
Novartis AG |
Organic compounds
|
|
AU2007261536C1
(en)
|
2006-06-16 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
VEGF antagonist formulations suitable for intravitreal administration
|
|
CN101541345A
(zh)
*
|
2006-09-25 |
2009-09-23 |
米迪缪尼有限公司 |
稳定化的抗体制剂和其应用
|
|
AU2007300221A1
(en)
*
|
2006-09-25 |
2008-04-03 |
Medimmune, Llc. |
Stabilized antibody formulations and uses thereof
|
|
SI2907827T1
(sl)
|
2006-11-02 |
2019-02-28 |
Genentech, Inc. |
Humanizirana protitelesa proti faktorju D in njihova uporaba
|
|
US20090111708A1
(en)
|
2007-05-11 |
2009-04-30 |
Seddon Johanna M |
Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
|
|
AR066660A1
(es)
|
2007-05-23 |
2009-09-02 |
Genentech Inc |
Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
|
|
ES2663512T3
(es)
*
|
2007-05-24 |
2018-04-13 |
Ablynx N.V. |
Secuencias de aminoácidos dirigidas contra RANK-L y polipéptidos que comprenden las mismas para el tratamiento de enfermedades y trastornos óseos
|
|
WO2009029587A2
(en)
|
2007-08-24 |
2009-03-05 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating macular degeneration
|
|
US20110177957A1
(en)
|
2008-04-18 |
2011-07-21 |
Tufts Medical Center, Inc., (f/k/a/ New England Medical Center Hospitals, Inc.) |
Polymorphisms Associated With Age-Related Macular Degeneration And Methods For Evaluating Patient Risk
|
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
|
US20110294682A1
(en)
|
2008-04-28 |
2011-12-01 |
The General Hospital Corporation |
Polynucleotides Associated With Age-Related Macular Degeneration and Methods for Evaluating Patient Risks
|
|
CN102076715B
(zh)
|
2008-06-25 |
2018-06-19 |
艾斯巴技术-诺华有限责任公司 |
免疫结合剂的溶解性优化
|
|
CN101724144A
(zh)
|
2008-11-03 |
2010-06-09 |
北京键凯科技有限公司 |
新型的多臂聚乙二醇及其制备方法和应用
|
|
US20120003641A1
(en)
|
2008-11-05 |
2012-01-05 |
Graham Robert R |
Genetic polymorphisms in age-related macular degeneration
|
|
US20120115925A1
(en)
|
2008-12-23 |
2012-05-10 |
Massachusetts Eye And Ear Infirmary |
Allelic Variants Associated with Advanced Age-Related Macular Degeneration
|
|
AU2009333100B2
(en)
|
2009-01-02 |
2014-08-14 |
Alcon Research, Ltd. |
In-situ refillable ophthalmic implant
|
|
WO2010085542A2
(en)
|
2009-01-23 |
2010-07-29 |
Novartis Ag |
Biomarkers related to age-related macular degeneration (amd)
|
|
AU2010208046B2
(en)
|
2009-01-29 |
2014-10-02 |
Forsight Vision4, Inc. |
Posterior segment drug delivery
|
|
WO2010132459A2
(en)
|
2009-05-11 |
2010-11-18 |
Cleveland Clinic Foundation |
Biomarkers for assessment of age-related macular degeneration
|
|
CN107858381A
(zh)
|
2009-07-02 |
2018-03-30 |
朗泽科技新西兰有限公司 |
醇生产方法
|
|
CA2781595C
(en)
|
2009-07-10 |
2016-07-05 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating macular degeneration
|
|
WO2011017229A2
(en)
|
2009-08-06 |
2011-02-10 |
Tufts - New England Medical Center |
Plasma complement components as expression markers for age-related macular degeneration and related phenotypes
|
|
US8221753B2
(en)
*
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
|
IN2012DN03362A
(enExample)
*
|
2009-11-19 |
2015-10-23 |
Merck Serono Sa |
|
|
BR112012012983A2
(pt)
|
2009-12-04 |
2020-09-15 |
Genentech Inc |
método para sintetizar um anticorpo multiespecífico, método para sintetizar um painel de anticorpos multiespecíficos, método para sintetizar um análogo de anticorpo, método para sintetizar um painel de análogos de anticorpo e composições
|
|
CN102108119A
(zh)
|
2009-12-25 |
2011-06-29 |
天津键凯科技有限公司 |
多臂聚乙二醇衍生物及其与药物的结合物和凝胶
|
|
SG188328A1
(en)
*
|
2010-09-03 |
2013-04-30 |
Stem Centrx Inc |
Novel modulators and methods of use
|
|
AR083677A1
(es)
|
2010-11-01 |
2013-03-13 |
Genentech Inc |
Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica
|
|
EP2694552B1
(en)
*
|
2011-04-07 |
2017-10-11 |
Amgen Inc. |
Novel egfr binding proteins
|
|
CA2850032C
(en)
|
2011-10-14 |
2022-06-07 |
Genentech, Inc. |
Anti-htra1 antibodies and methods of use
|
|
TWI593705B
(zh)
*
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
|
JP6051998B2
(ja)
|
2012-03-30 |
2016-12-27 |
日油株式会社 |
マルチアーム型ポリエチレングリコール誘導体、その中間体及び製造方法
|
|
CN107318267B
(zh)
|
2013-08-12 |
2021-08-17 |
豪夫迈·罗氏有限公司 |
用于治疗补体相关的病症的组合物和方法
|
|
DK3042205T3
(da)
|
2013-09-06 |
2020-03-02 |
Hoffmann La Roche |
Fremgangsmåde til forbedring af antistofstabilitet
|
|
PE20161440A1
(es)
|
2014-05-01 |
2017-01-26 |
Genentech Inc |
Variantes del anticuerpo anti-factor d y sus usos
|